Drug Trial Radar · NCT05277168
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
May 30, 2022
Primary completion
May 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-A1904Drug
Single Arm :It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: The first cycle of administration, up to 21 days.
- Maximum tolerated dose (MTD)Time frame: The first cycle of administration, up to 21 days.
- Recommended Phase 2 Dose (RP2D)Time frame: The first cycle of administration, up to 21 days.
- Adverse events (AEs) and serious adverse events (SAEs)Time frame: From the signing of informed consent form to the end of safety follow-up period (90 days after the last dose).
Locations
28 sites in 4 countries. Site status is shown where the registry gives one.
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida · Active not recruiting
Comprehensive Hematology Oncology
St. Petersburg, Florida · Terminated
LSU Health Sciences Center
New Orleans, Louisiana · Active not recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Terminated
Rhode Island Hospital
Providence, Rhode Island · Terminated
Prisma Health
Greenville, South Carolina · Active not recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Central Coast Local Health District
Gosford, New South Wales, Australia · Completed
Sydney South West Private Hospital
Liverpool, New South Wales, Australia · Completed
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia · Completed
Genesis Care North Shore
St Leonards, New South Wales, Australia · Completed
Macquarie University
Sydney, New South Wales, Australia · Completed
Westmead Hospital
Westmead, New South Wales, Australia · Completed
Gold Coast Private Hospital
Southport, Queensland, Australia · Completed
Peninsula and South Eastern Haematology & Oncology Group (PASO)
Frankston, Victoria, Australia · Completed
One Clinical Research (OCR)
Nedlands, Western Australia, Australia · Completed
National Institute of Oncology, Arensia Research Clinic
Chisinau, Moldova · Active not recruiting
Dong-A University Hospital
Busan, South Korea · Recruiting
Chungbuk National University Hospital
Cheongju-si, South Korea · Recruiting
Ajou University Hospital
Gyeonggi-do, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam, South Korea · Recruiting
CHA Bundang Medical Centre
Seongnam-si, South Korea · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Korea University Guro Hospital
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.